- OTC private label products launched with all major retailers
- A+ health line of OTC products launched on Amazon.
- Bionafem - the first bilingual labeled OTC Oral Contraceptive launched.
- Initiatives to internalize R&D initiated with signing an definitive agreement with
Nuwill for acquiring the company. Closure in 2020.
- 8 product approvals obtained from FDA and 4 more ANDA's filed with FDA.
- Bion completes 5 years in the US generic space.
- 4 product approval from own R&D and launch.
- First day 1 launches of products on patent expiry.
- OTC portfolio internalized. Infrastructure and personnel set up for onboarding OTC.
- Licensing agreement signed for 1st branded OTC product.
- 6 ANDA's filed with the FDA
- Complete re-launch of all product in own label.
- Invstement in Core Rx - A CDMO in Florida.
- 8 products filed with FDA
- Internailized 2 RX products from partners.
- MSA signed with Core Rx for commercializing.
- 5 products developed and filed from Core Rx.
- Bionpharma commercial in all states.
- Products launched with all retailers.
- Organization grows from 6 to 12 people Office established in NC.
- All marketing partners onboarded.
- 1st product filed from own R&D efforts.
- 2nd round of funding closed.
- Board of directors appointed.
- Two Partnership agreement for development of products concluded.
- Commercial product in licensing concluded.
- 3 PL in place for distributing products.
- State licenses obtained.
- 1st Commercial product launched.
- Acquisition of product portfolio concluded.
- Bionpharma Incorporated.
- 1st round funding closed
- Inlicensing agreement signed with pharmascience
- 1st product put into development